Given that inhibition of PAI‐1 augments the activities of the endogenous plasminogen activators, PAI‐1 has been recognized as a potential therapeutic target for fibrinolytic treatment of thrombotic disorders 2, 3. The gene discussed is SERPINE1; the disease is thrombotic disease.